Welcome to our dedicated page for Mangoceuticals SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mangoceuticals, Inc. (MGRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Mangoceuticals describes itself as a Texas corporation whose common stock trades on the Nasdaq Capital Market, and its Form 8-K filings and related documents offer detailed insight into material agreements, financings, and corporate events.
Recent Mangoceuticals filings include Form 8-K reports on private placements of common stock, registered direct offerings and concurrent private placements of warrants, conversions of preferred stock and convertible notes into common stock, and warrant exercises. The company has also filed 8-Ks describing a lease agreement for office space in Dallas, Texas, a separation agreement with a former chief operating officer, and the resignation of a president and director. Other filings outline amendments to promissory notes, issuance of warrants, and the use of an equity line of credit arrangement.
Mangoceuticals’ SEC reports also document its entry into, and subsequent mutual rescission of, a Master Distribution Agreement for exclusive licensing and distribution rights to the nutraceutical Diabetinol in the United States and Canada. Additional 8-Ks reference company press releases about topics such as GLP-1–related programs and other corporate announcements, which are incorporated by reference as exhibits.
On this page, you can review Mangoceuticals’ 8-K filings and other available forms to understand how the company structures financings, manages key agreements, and reports significant events. AI-powered summaries on Stock Titan help explain the main points of lengthy documents, highlight important terms such as conversion prices or warrant conditions, and point out sections related to capital structure and obligations. Real-time updates from EDGAR, along with access to historical filings, allow investors and researchers to monitor MGRX’s regulatory history, governance changes, and transaction activity in a single, organized view.
Mangoceuticals (MGRX) reported a corporate update. The company furnished an 8-K noting it issued a press release discussing a partnership with Eli Lilly and Novo Nordisk to deliver affordable access to Zepbound and Wegovy. The press release is included as Exhibit 99.1 and incorporated by reference.
The update was disclosed under Item 8.01 (Other Events). No financial terms or timelines were provided in the excerpt.
Mangoceuticals, Inc. (MGRX) reported multiple corporate actions. The company signed a five-year Lease beginning November 1, 2025 for approximately 2,467 sq. ft. plus 1,253 sq. ft. of shared space at 17130 Dallas Parkway. Monthly Base Rent totals $4,852, and the company will also pay its 14.81% pro‑rata share of taxes, insurance, and common area costs. At signing, it prepaid $6,141 for the first month’s Base and Additional Rent and posted a $14,557 security deposit. The Lease includes a right of first refusal to purchase the Premises.
The company entered into a Separation Agreement with COO Amanda Hammer, whose employment ended October 22, 2025. Mangoceuticals will pay nine months of salary in equal monthly installments starting November 1, 2025, and may request optional consulting at $86 per hour. No material termination penalties were incurred beyond the disclosed separation payments.
Under Item 3.02, holders converted Series B Convertible Preferred Stock into common stock: Indigo Capital LP converted 500 shares into 366,667 common shares at a $1.50 conversion price, and Platinum Point Capital, LLC converted 32 shares into 23,466 common shares at the same price. The company cited the Section 3(a)(9) exemption; resale of conversion shares has been registered on an effective registration statement.
Mangoceuticals, Inc. reports an Amendment No. 5 to a Schedule 13D filed by Jacob D. Cohen and The Tiger Cub Trust showing combined beneficial ownership of 2,044,356 shares, representing 14.6% of the outstanding common stock (based on 13,266,437 shares outstanding as of September 11, 2025). The filing discloses a May 2, 2025 $100,000 loan from The Tiger Cub Trust at 18% annual interest that was amended on July 21, 2025 into an Amended and Restated Convertible Promissory Note (A&R Note) convertible at $1.785 per share and accompanied by warrants to purchase 50,000 shares at $1.815 per share. Mr. Cohen gifted 200,000 shares to the Trust and was granted a 500,000 share bonus plus options to buy 2,000,000 shares (exercise price $2.30, 10-year term) with specified vesting.
Mangoceuticals, Inc. entered into a private placement of its common stock with accredited investors. The company sold 709,677 shares of restricted common stock at $1.55 per share, raising a total of $1,100,000 in gross proceeds. The investors received piggyback registration rights for one year following the subscription dates, meaning their shares can be included in certain future registration statements if the company registers other shares.
The transaction was completed through four Subscription Agreements with five accredited investors and relied on exemptions from SEC registration under Section 4(a)(2) and/or Rule 506 of Regulation D. There was no general solicitation, no underwriters or agents were involved, and no underwriting discounts or commissions were paid. The issued securities are subject to transfer restrictions and bear legends stating they are unregistered and may only be resold pursuant to registration or a valid exemption.
Mangoceuticals, Inc. filed a Form 8-K reporting entry into a Mutual Rescission and Release Agreement with Navy Wharf, Ltd., effective July 30, 2025, terminating and rescinding the March 24, 2025 Master Distribution Agreement (MSA) that granted exclusive U.S./Canada licensing rights to Diabetinol trade dress and related IP.
Under the original MSA the Company issued 1,000,000 restricted shares to Navy Wharf and agreed to pay 10% of net sales as royalty. The Rescission Agreement provides mutual releases of obligations, requires Navy Wharf to cancel the Navy Shares, and states no material early termination penalties were incurred by the Company. Separately, on July 29, 2025 a warrant holder exercised for 198,000 shares at $1.50, raising $297,000; those shares were issued as 198,000 net shares under an exemption from registration. Exhibit 10.1 (Rescission Agreement) is filed.
Mangoceuticals has received a Notice of Effectiveness from the SEC for their Form S-3 registration statement, effective as of June 24, 2025, at 4:00 P.M. The Form S-3 (File Number: 333-288039) is a shelf registration statement that allows the company to offer and sell securities to the public.
A Form S-3 filing indicates that Mangoceuticals meets certain eligibility requirements, including being current with SEC reporting obligations. This registration enables the company to access capital markets more efficiently by allowing them to register securities for future public offerings. The effectiveness notice means the company can now proceed with securities offerings under this registration statement.
Filing highlight: Mangoceuticals, Inc. (CIK 0001938046; symbol MGRX) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission.
The SEC declared the company’s Form S-1 registration statement (File No. 333-287689) effective at 5:00 p.m. on June 18, 2025. This notice confirms that the registration statement has completed the Commission’s review and is now operative.
No further details—such as the size, terms, or purpose of the registered securities—were disclosed in the notice.